Published in final edited form as:

Radiother Oncol. 2019 May ; 134: 89–95. doi:10.1016/j.radonc.2019.01.026.

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy

Christopher L. Tinkle, MD, PhD^a, Noelle L. Williams, MD^b, Huiyun Wu, MSc^c, Jianrong Wu, PhD^d, Sue C. Kaste, DO^{e,f,g}, Barry L. Shulkin, MD, MBA^{e,f}, Aimee C. Talleur, MD^h, Jamie E. Flerlage, MD, MS^g, Melissa M. Hudson, MD^g, Monika L. Metzger, MD^g, and Matthew J. Krasin, MD^a

^aDepartment of Radiation Oncology, St. Jude Children's Hospital, Memphis, TN, US

^bDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, US

^cDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, US

^dDepartment of Biostatistics, University of Kentucky, Lexington, KY, US

^eDepartment of Diagnostic Imaging St. Jude Children's Research Hospital, Memphis, TN, US

^fDepartment of Radiology, University of Tennessee Health Science Center, Memphis, TN, US

^gDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, US

^hDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, US.

Abstract

Background and purpose: The use of radiotherapy (RT) for pediatric patients with Hodgkin lymphoma (HL) experiencing disease progression or recurrence (15%) is controversial. We report treatment patterns and outcomes for pediatric patients with refractory/recurrent HL (rrHL) treated with curative-intent RT.

Materials and methods: Forty-six patients with rrHL treated with salvage RT at our institution were identified. All received risk-adapted, response-based frontline therapy and were retrieved with cytoreductive regimens followed by RT to failure sites, with or without autologous hematopoietic cell transplantation (AHCT). Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT.

Corresponding author: Christopher L. Tinkle, MD, PhD, Department of Radiation Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 210, Memphis, TN, US, 38105. Tel (901) 5958735; Fax (901) 595-3113; christopher.tinkle@stjude.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Results: RT was administered as part of frontline therapy in 70% of patients, omitted for early response assessment in 13%, or deferred for primary progression in 17%. AHCT was omitted in 20% of patients. Median initial and salvage dose/site were 25.5Gy and 30.6Gy, respectively. Eight patients experienced progression. Two died without progression (median follow-up from salvage RT=3.8 years). The 5-year CIN of LF after salvage RT was 17.7% (95% confidence interval [CI], 8.2%–30.2%). The 5-year freedom from subsequent treatment failure and overall survival (OS) was 80.1% (95% CI, 69.2%–92.6%) and 88.5% (95% CI, 79.5%–98.6%), respectively. Inadequate response to salvage systemic therapy ($p=0.048$) and male sex ($p=0.049$) were significantly associated with LF after salvage RT.

Conclusion: rrHL is responsive to salvage RT, with low LF rates after moderate doses. OS is excellent, despite refractory disease. Initial salvage therapy response predicts subsequent LF.

INTRODUCTION

Despite excellent prospects for long-term survival, 15% of children and young adults with Hodgkin lymphoma (HL) experience primary disease progression or recurrence [1,2]. Due to the success of upfront therapy, there are limited opportunities for investigating prospective salvage-therapy programs and to individualize second-line treatment. Various salvage treatments have been employed, yet contemporary pediatric approaches generally use second-line systemic therapy with novel agents and/or combinations followed by high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT). The addition of brentuximab vedotin (BV) as maintenance therapy after transplant has also been explored, based on encouraging results in adults [3–9]. Radiotherapy (RT) is often employed in salvage regimens. The impact of curative-intent RT in refractory or recurrent Hodgkin lymphoma (rrHL) remains controversial.

Concerns regarding rrHL salvage RT include impact of local tumor control on survival considering potentially compounded toxicity, along with questions regarding optimal radiation field, dose, and sequencing in relation to AHCT. Factors supporting salvage RT include lack of RT cross-resistance in many chemotherapy-refractory patients [10–14] and predominantly nodal recurrence at initial disease sites [15–17]. Nodal failure has influenced RT field design; for example, total lymphoid irradiation (TLI) has been employed as “quasi-systemic therapy” to treat nodal-restricted recurrent disease in radiation-naïve patients before they undergo AHCT [18]. However, data increasingly suggest that some “low-risk” relapse patients, can be treated effectively with standard frontline chemotherapy regimens and limited RT, typically involved-field RT (IFRT) or involved-site RT (ISRT), alone [5,19–22]. Primary progressive disease, time to relapse, and chemoresistance appear to be the most consistent prognostic factors associated with survival after frontline treatment failure. How these factors influence local tumor control is less clearly established [5,23,22,24–26,20,27,28].

We reviewed our experience with pediatric and young adult patients with rrHL who were treated with curative-intent RT as a component of salvage therapy in order to assess local tumor control outcomes and identify prognostic factors. We limited analysis to patients treated with homogeneous initial and relapse therapies at our institution, including primary

therapy of risk-stratified, response-adapted chemoradiotherapy and retrieval therapy of intense cytoreductive systemic regimens and RT with or without AHCT.

MATERIALS AND METHODS

From March 2000–December 2015, 357 patients with newly diagnosed HL were treated at our institution. Seventy-six experienced frontline treatment failure due to progressive or recurrent disease. Thirty patients were excluded because they received frontline or salvage therapy elsewhere (Supplementary Fig. 1). Our Institutional Review Board (IRB) approved the study. Frontline therapy, follow-up, and treatment failure assessment have been detailed previously [20, 29–31] (Supplementary Methods and Table 1).

Salvage therapy

Salvage regimens were based on physician recommendations and influenced by initial therapy course and intensity, timing and site(s) of treatment failure, and patient status. Most patients were retrieved with high-dose methotrexate, ifosfamide, etoposide, and dexamethasone (MIED) (n = 17) or with vinorelbine and gemcitabine with or without ifosfamide (VG) (n = 18). In cases of localized late treatment failure after initial treatment with chemotherapy only, patients received Stanford V chemotherapy (n = 6), whereas regimens of vincristine, etoposide, prednisone, and doxorubicin (OEPA), cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) (n = 2), and bendamustine and BV (n = 2) were used in patients treated recently. For high-risk patients who responded to the first or subsequent courses of salvage chemotherapy, AHCT with high-dose chemotherapy conditioning followed. Transplant-conditioning regimens consisted of carmustine, etoposide, cytarabine, and melphalan (BEAM) (n = 31) or busulfan/melphalan (n = 2). One patient in whom synchronous recurrent HL and myeloid sarcoma were diagnosed at first relapse underwent total body irradiation (TBI) followed by cyclophosphamide treatment. Typically, salvage RT was administered to sites involved at time of treatment failure in patients who received upfront RT or to all sites of initial disease in patients where upfront RT was omitted. Salvage RT followed AHCT or retrieval chemotherapy in high- and low-risk patients, respectively. Photon irradiation was delivered to all patients at diagnosis and/or progression. A dose of 30.6Gy was delivered unless prior normal-tissue exposure or size of the salvage RT field limited safe delivery. RT delivery techniques evolved over time from simple field arrangements encompassing complete nodal station(s) to conformal RT, including IMRT, restricted to sites of nodal progression.

Response assessment

Adequate responses to initial salvage therapy included complete response (CR) (defined as reduction of $\geq 75\%$ in tumor size on a CT scan [using the product of two largest tumor dimensions on an axial plane to determine size] and negative gallium or PET scans) and partial response (PR) (defined as 50%–74% reduction in tumor size on CT scan, regardless of PET avidity). Inadequate response was defined as response not meeting these criteria. No patient who experienced CR had a positive PET scan.

Statistical analysis

Treatment failure was defined as development of new lesions; >25% increase in size of existing lesions, based on bi-dimensional measurements on CT; or abnormal uptake on gallium or PET scans. Progressive disease was defined as treatment failure within 3 months of initial therapy completion, early relapse as treatment failure from 3 to 12 months after initial therapy completion, and late relapse as treatment failure more than 12 months after initial therapy completion [20]. Freedom from subsequent treatment failure (FFSTF) was defined as time from start of salvage RT to disease progression or death, whichever occurred first. Overall survival (OS) was defined as time from start of salvage RT to death. Patients without an event were censored at last follow-up date or the last date they were known to be free of an event. FFSTF and OS were estimated using the Kaplan-Meier method, presented with 95% confidence intervals (CIs), and compared using the log-rank test. CINs of LF from the end of salvage RT, with other events considered as competing risk, were estimated by the method of Kalbfleisch and Prentice ([32]) and compared using the Gray test. To identify predictors of LF after salvage RT, cumulative-incidence regression analysis was used. Significance was determined by the Wald test and results were summarized by the hazard ratio (HR). All analyses were performed in SAS software (version 9.1, SAS Institute, Inc., Cary, NC).

RESULTS

Baseline patient and treatment characteristics

Table 1 lists the patient (n=46) and treatment characteristics. The median age was 16.5 years (range, 4.7–22.0 years) at initial diagnosis and 17.5 years (range, 6.0–23.9 years) at first treatment failure. Advanced disease presentation was observed in 32 patients (70%) and nodular sclerosing histologic variant in 33 patients (72%) at initial diagnosis. Disease progression less than 3 months post-primary therapy occurred in 10 patients (22%), and relapse occurred in 36 (78%). The median time to first recurrence after completion of primary therapy was 10.7 months (range, 1.2–42.7 months). Lymph nodes were a component of initial failure in 44 patients (96%). Failure in a site distinct from the involved sites at diagnosis was documented in eight patients (17%). Frontline consolidative RT to a median dose of 25.5Gy was delivered to 32 patients (70%), was deferred in eight patients (17%) because of progressive disease, and was omitted in six patients (13%) based on protocol-defined response criteria. Of the patients who received frontline RT, IFRT was employed in the majority of cases (88%). While IFRT was most commonly used at salvage, a large proportion of patients were treated with ISRT (42%). Likewise, conformal RT through the use of IMRT was used more frequently at the time of salvage therapy (3% at frontline and 22% at salvage). The median salvage RT was 30.6Gy, with a range of 12 to 43.2Gy.

Response to frontline and salvage regimens

Table 2 summarizes frontline and salvage therapies employed, as well as types of primary disease failure, responses to salvage therapies, and overall disease outcomes. When frontline RT was omitted based on a favorable response to chemotherapy (n=6), two patients experienced early relapse and four late relapse, all of which were nodal. Four of these six

patients experienced recurrence in at least one site distinct from initial disease site(s). All of these patients had adequate response to salvage chemotherapy and subsequently received salvage RT to a median 30.6Gy (range, 25.5–30.6Gy) to sites of recurrent disease without AHCT. Two patients progressed after salvage RT; one entirely within the previously irradiated site and the other within the prior RT site plus a new, distant nodal site. These two patients were then treated with re-induction chemotherapy and AHCT followed by RT to sites of second recurrence (30.6 Gy to sites previously unirradiated and 25.5 Gy to sites previously treated). They had no evidence of disease at last follow-up at 1.1 and 3.3 years post treatment, respectively.

Of the 32 patients treated with primary chemoradiation, two experienced progressive disease within 3 months of primary chemoradiation, 16 experienced early relapse, and 14 experienced late relapse. All patients with adequate response to salvage chemotherapy underwent AHCT followed by salvage RT, except for three patients who were considered low risk for recurrence and whose salvage therapy was chemoradiation only. These three patients have experienced long-term disease control after being treated with salvage chemotherapy followed by mantle-field irradiation to 25.5Gy and are at least 5 years post-salvage therapy. Figure 1 shows a patient treated with frontline dose-reduced chemotherapy and response-based RT followed by salvage chemotherapy, AHCT, and consolidative ISRT.

Of the 10 patients with primary progressive disease, six experienced disease progression while receiving frontline chemotherapy, two experienced progression while receiving frontline RT, and two experienced progression within 3 months of frontline chemoradiation completion. Seven of these patients experienced CR to initial salvage therapy and underwent AHCT followed by consolidative RT. All remain alive with no evidence of disease, except for one patient who died of respiratory failure attributed to transplant complications.

Disease control, survival outcomes, and long-term toxicity

With a median follow-up from end of salvage RT of 3.8 years (range, 0.3–13.7 years), eight patients experienced subsequent disease progression. Failure patterns after salvage RT included local failures (n=4), defined as being within salvage radiation field, and synchronous local and distant failures (n=4). Median time to subsequent disease progression post-salvage RT was 6.7 months (range, 0.4–32.9 months). Five-year CIN of LF post-salvage RT was 17.7% (95% CI, 8.2%–30.2%) (Fig. 2A). Analysis of LF after salvage RT by response to first salvage chemotherapy demonstrated a 5-year CIN of LF of 12.4% (95% CI, 4.5%–25.1%) for patients with adequate response to salvage chemotherapy, compared to 35% (95% CI, 10.0%–64.3%) for patients with an inadequate response ($p = 0.0475$) (Fig. 2B and C).

Cumulative-incidence regression analysis of predictors of LF post-salvage RT revealed inadequate response to first salvage chemotherapy ($p=0.048$) and male sex ($p=0.049$) were significantly associated with risk of LF (Table 3). However, additional variables, including the clinical variable of age; disease characteristics of primary risk category and primary disease failure type; and treatment factors of salvage RT dose, repeat RT, and receipt of AHCT, were not significantly associated with LF post-salvage RT.

The five-year estimate of FFTF for all patients was 80.1% (95% CI, 69.2%–92.6%) (Fig. 3A). The five-year estimate of OS was 88.5% (95% CI, 79.5%–98.6%) (Fig. 3B). The cause of death was either HL (n=4) or treatment-related respiratory failure (n=2). Of those patients who succumbed to HL, the median time from initial diagnosis to death was 31.4 months (range, 14.9–47.3 months).

The most common grade 3 or higher late toxicities (>3 months from end of salvage RT) were pulmonary (8.7%), cardiac (6.5%), gastrointestinal (2.2%), and other (2.2%). Grade 2 hypothyroidism was the most common endocrine toxicity (n=7), while four patients experienced significant pulmonary toxicity, resulting in death in two. Second malignancies developed in two patients (4.3%), both of which were considered outside the primary or salvage RT fields. One patient was found to have Burkitt lymphoma of the small intestine 6 years from salvage RT which included a modified mantle field after initial RT to a mantle field, while one patient was diagnosed with a forearm melanoma after 1 year of salvage RT also consisting of a modified mantle field after initial treatment to a mantle field.

DISCUSSION

We examined patterns of care and treatment outcomes for 46 pediatric and young adult patients with progressive or relapsed HL treated with curative-intent salvage RT. Despite initially recalcitrant disease, we demonstrated a salvage treatment paradigm of intensive chemotherapy and moderate-dose RT limited to sites of refractory disease, with or without AHCT, provides durable local control and encouraging long-term survival outcomes. Five-year CIN of LF after salvage RT was 17.7% (95% CI, 8.2%–30.2%), whereas the FFSTF was 80.1% (95% CI, 69.2%–92.6%). Overall survival was 88.5% (95% CI, 79.5%–98.6%). While the sequencing of RT in relation to other components of therapy and the restricted targeting of regions with recurrent disease have remained a consistent part of our salvage treatment paradigm, our approach to RT has evolved to the current use of involved nodal RT with proton therapy employed in most cases.

Pediatric-specific data for rrHL are limited. Most reports have been specific to adult populations or include few younger patients. However, there is particular concern for long-term morbidity in the younger population leaving important questions regarding outcomes and optimal RT volume, dose, and sequencing with transplant. For example, use of accelerated TLI with or without IFRT as a component of salvage therapy in radiation-naïve patients has resulted in excellent survival outcomes [18]; however, this is less suitable for children, given potential for unacceptable toxicities [33]. Several retrospective studies have examined the role of salvage IFRT in the peri-transplant setting, and some reports have demonstrated PFS advantage with the addition of IFRT [34–36]. Our study has further extended these findings by providing novel data regarding treatment patterns and outcomes specific to pediatric and young adult patients within this relatively uniformly treated cohort. Moderate-dose salvage RT, with or without AHCT, has encouraging long-term local control (82.3% at 5 years). Further, of the four patients who developed synchronous local and distant progression, two experienced progression outside conventional TLI field (liver and peripheral lung).

Several groups have tried to identify factors predictive of survival outcomes in children and adults with HL that was refractory to primary therapy or with relapsed disease after initial treatment [5]. Variables identified in children and adolescents include progressive disease during frontline therapy [5] and response to initial salvage chemotherapy [20]. Results have been mirrored in adult settings ([18]). Other factors associated with poor survival in pediatric patients include extranodal disease at time of treatment failure, a mediastinal mass at time of transplant, and presence of B symptoms at relapse [23,37]. In our study, adequate response to initial salvage therapy was associated with lower risk of subsequent LF. Although several studies have shown many patients with rrHL receiving chemotherapy alone do not exhibit cross-resistance to RT [13,38], our data suggest subsequent chemosensitivity predicts enhanced response to radiation or, conversely, hint at existence of a population in which salvage RT may ultimately be omitted [39–41]. Male sex has been associated with inferior survival in adults with HL [42,43], but is not a consistent finding; in a larger pediatric study of AHCT of rrHL, female patients had significantly worse outcomes [44]. Our finding of an association between male sex and LF awaits further investigation in larger pediatric patient cohorts.

Among the 38 patients who had adequate response to initial salvage therapy in our study, nine (20%) did not undergo AHCT, but durable tumor control was established in all of them after salvage therapy. They remain alive and disease free. These findings support the notion that not all patients who experience disease relapse after frontline therapy require AHCT, particularly if their response to initial salvage therapy is adequate and time to recurrence is long [5,20,27]. Although AHCT is curative in 50% of adult patients with chemotherapy-sensitive primary disease and has been established as standard of care for patients with rrHL [3,4], a randomized trial of AHCT compared to salvage chemoradiation would be required to determine whether AHCT improves outcomes for specific patient groups in the pediatric setting [26]. Substantial limitations preclude this type of study.

Although optimal integration of novel systemic therapy options into the salvage treatment paradigm for the pediatric patient population continues to evolve, these agents are likely to influence patient selection for salvage RT and AHCT. BV is a promising agent in the salvage setting, both for patients who have progressed after undergoing AHCT or two cycles of salvage chemotherapy and are not candidates for transplant ([45]) and for patients who have completed AHCT and are at high risk for subsequent progression ([8,46]). In addition to targeted chemotherapy, immunotherapy with programmed death 1 (PD-1) blockade has shown promising response rates and acceptable safety in patients with rrHL whose disease has progressed after several lines of salvage therapy, including AHCT and BV ([47,9]).

CONCLUSIONS

This study represents one of the largest childhood cohorts of rrHL published, with a focus on salvage RT approaches in this vulnerable population and on the impact of clinical variables on local tumor control. We observed a low CIN of LF after moderate-dose salvage RT (17.7%) at 5 years, and an association with enhanced local control in patients who had adequate response to induction salvage chemotherapy. These data contribute to the growing

pediatric literature highlighting the role of salvage RT and reaffirm the importance of large, risk-stratified, prospective trials specific to rrHL and patient population.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

The authors would like to thank Keith A. Laycock, PhD, ELS, for scientific editing of the manuscript and Brandon Bianski for assistance with data extraction.

Financial disclosure: This work was supported in part by the American Lebanese Syrian Associated Charities (ALSAC) and by National Cancer Institute grant P30 CA021765 (St. Jude Cancer Center Support Grant). The funding sources did not have a role in study design, the collection, analysis or interpretation of data, in the writing of the report, or in the decision to submit the article for publication.

Abbreviations:

RT	radiotherapy
HL	Hodgkin lymphoma
rrHL	refractory/recurrent Hodgkin lymphoma
AHCT	autologous hematopoietic cell transplantation
CIN	cumulative incidence
LF	local failure
CI	confidence interval
FFSTF	freedom from subsequent treatment failure
OS	overall survival
TLI	total lymphoid irradiation
IFRT	involved-field radiotherapy
ISRT	involved-site radiotherapy
IRB	Institutional Review Board
MIED	methotrexate, ifosfamide, etoposide, and dexamethasone
VG	vinorelbine and gemcitabine
OEPA	vincristine, etoposide, prednisone, and doxorubicin
COPDAC	cyclophosphamide, BV, brentuximab vedotin; vincristine, prednisone, and dacarbazine
BEAM	carmustine, etoposide, cytarabine, and melphalan

TBI	total body irradiation
CR	complete response
PR	partial response
HR	hazard ratio
PD-1	programmed death 1
PTV	planning target volume
95% IDL	95% isodose line.

REFERENCES

1. Claviez A, Sureda A, Schmitz N (2008). Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma. *Bone Marrow Transplant* 42 Suppl 2:S16–24. [PubMed: 18978738]
2. Hodgson DC, Hudson MM, Constine LS (2007). Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. *Semin Radiat Oncol* 17 (3):230–242. [PubMed: 17591570]
3. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993). Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. *Lancet* 341 (8852):1051–1054. [PubMed: 8096958]
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V, German Hodgkin's Lymphoma Study G, Lymphoma Working Party of the European Group for B, Marrow T (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet* 359 (9323):2065–2071. [PubMed: 12086759]
5. Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter HG, Bokkerink JP, Riepenhausen M, Luders H, Potter R, Ruhl U, Dal/Gpoh (2005). Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. *J Clin Oncol* 23 (25):6181–6189. [PubMed: 16135485]
6. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM (2009). Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a Children's Oncology Group report. *J Clin Oncol* 27 (9):1456–1461. [PubMed: 19224841]
7. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, London WB, Chen L, de Alarcon P (2015). Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a Children's Oncology Group report. *Pediatr Blood Cancer* 62 (1):60–64. [PubMed: 25308760]
8. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J, Group AS (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 385 (9980):1853–1862. [PubMed: 25796459]
9. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, Keynote (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. *J Clin Oncol* 35 (19):2125–2132. [PubMed: 28441111]
10. Brada M, Eeles R, Ashley S, Nichols J, Horwich A (1992). Salvage radiotherapy in recurrent Hodgkin's disease. *Ann Oncol* 3 (2):131–135. [PubMed: 1606082]

11. Leigh BR, Fox KA, Mack CF, Baier M, Miller TP, Cassady JR (1993). Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. *Int J Radiat Oncol Biol Phys* 27 (4):855–862. [PubMed: 8244815]
12. Fox KA, Lippman SM, Cassady JR, Heusinkveld RS, Miller TP (1987). Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. *J Clin Oncol* 5 (1):38–45. [PubMed: 3806158]
13. Uematsu M, Tarbell NJ, Silver B, Coleman CN, Rosenthal DS, Shulman LN, Canellos G, Weinstein H, Mauch P (1993). Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. *Cancer* 72 (1): 207–212. [PubMed: 7685241]
14. Roach M 3rd, Kapp DS, Rosenberg SA, Hoppe RT (1987). Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. *J Clin Oncol* 5 (4):550–555. [PubMed: 3559648]
15. Mundt AJ, Sibley G, Williams S, Hallahan D, Nautiyal J, Weichselbaum RR (1995). Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 33 (2):261–270. [PubMed: 7673013]
16. Macdonald DA, Ding K, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM (2007). Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. *Ann Oncol* 18 (10):1680–1684. [PubMed: 17846017]
17. Pezner RD, Nademanee A, Niland JC, Vora N, Forman SJ (1995). Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. *Radiother Oncol* 34 (1): 23–29 [PubMed: 7792395]
18. Rimner A, Lovie S, Hsu M, Chelius M, Zhang Z, Chau K, Moskowitz AJ, Matasar M, Moskowitz CH, Yahalom J (2017) Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. *Int J Radiat Oncol Biol Phys* 97 (5) :1066–1076. [PubMed: 28332991]
19. James ND, Kingston JE, Plowman PN, Meller S, Pinkerton R, Barrett A, Sandland R, McElwain TJ, Malpas JS (1992). Outcome of children with resistant and relapsed Hodgkin's disease. *Br J Cancer* 66 (5) :1155–1158. [PubMed: 1457357]
20. Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, Sandlund JT, Howard SC (2010). Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. *Cancer* 116 (18):4376–4384. [PubMed: 20564743]
21. Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, Diehl V, Josting A (2007). Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. *J Clin Oncol* 25 (15):2000–2005. [PubMed: 17420510]
22. Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG, United Kingdom Children's Cancer Study G (2004). Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. *J Pediatr Hematol Oncol* 26 (11):740–745. [PubMed: 15543009]
23. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, Agarwal R (2004). Highdose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. *J Clin Oncol* 22 (22):4532–4540. [PubMed: 15542804]
24. Akhtar S, El Weshi A, Rahal M, Abdelsalam M, Al Hussein H, Maghfoor I (2010). High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. *Bone Marrow Transplant* 45 (3):476–482. [PubMed: 19734949]
25. Harris RE, Termuhlen AM, Smith LM, Lynch J, Henry MM, Perkins SL, Gross TG, Warkentin P, Vlachos A, Harrison L, Cairo MS (2011). Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. *Biol Blood Marrow Transplant* 17 (2):249–258. [PubMed: 20637881]
26. Shafer JA, Heslop HE, Brenner MK, Carrum G, Wu MF, Liu H, Ahmed N, Gottschalk S, Kamble R, Leung KS, Myers GD, Bollard CM, Krance RA (2010). Outcome of hematopoietic stem cell

transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. *Leuk Lymphoma* 51 (4):664–670. [PubMed: 20367182]

27. Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C, Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y, Robert A, Landman-Parker J (2012). Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Societe Francaise de Lutte Contre le Cancer des Enfants et des Adolescents (SFCE). *Br J Haematol* 158 (5):649–656. [PubMed: 22757721]
28. Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD (2014). Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. *Pediatr Blood Cancer* 61 (4):579–586. [PubMed: 24504790]
29. Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP (2012). Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. *JAMA* 307 (24):2609–2616. [PubMed: 22735430]
30. Flerlage J (2006). Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma. ClinicalTrials.gov Identifier: NCT00352027. <https://clinicaltrials.gov/ct2/show/NCT00352027?id=NCT00846742+QR+NCT00352027&rank=2&load=cart>.
31. Rubnitz J (2009). Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma. ClinicalTrials.gov Identifier: NCT00846742. <https://clinicaltrials.gov/ct2/show/NCT00846742?id=NCT00846742+QR+NCT00352027&rank=1&load=cart>.
32. Prentice RL, Kalbfleisch JD, Peterson AV Jr., Flournoy N, Farewell VT, Breslow NE (1978). The analysis of failure times in the presence of competing risks. *Biometrics* 34 (4):541–554 [PubMed: 373811]
33. Jules-Elysee K, Stover DE, Yahalom J, White DA, Gulati SC (1992). Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. *Am Rev Respir Dis* 146 (2):485–491. [PubMed: 1489145]
34. Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK, Yuan J (2017). Role of Consolidative Radiation Therapy After Autologous Hematopoietic Cell Transplantation for the Treatment of Relapsed or Refractory Hodgkin Lymphoma. *Int J Radiat Oncol Biol Phys* 99 (1):94–102. [PubMed: 28816170]
35. Kahn S, Flowers C, Xu Z, Esiashvili N (2011). Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? *Int J Radiat Oncol Biol Phys* 81 (1):175–180. [PubMed: 20732769]
36. Poen JC, Hoppe RT, Horning SJ (1996). High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. *Int J Radiat Oncol Biol Phys* 36 (1):3–12. [PubMed: 8823253]
37. Giulino-Roth L, O'Donohue T, Chen Z, Trippett TM, Klein E, Kernan NA, Kobos R, Prockop SE, Scaradavou A, Shukla N, Steinherz PG, Moskowitz AJ, Moskowitz CH, Boulad F (2017). Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. *Leuk Lymphoma*:1–10.
38. Wirth A, Corry J, Laidlaw C, Matthews J, Liew KH (1997). Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. *Int J Radiat Oncol Biol Phys* 39 (3):599–607. [PubMed: 9336139]
39. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G (1978). Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. *Cancer Chemother Pharmacol* 1 (1):53–59. [PubMed: 373908]
40. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, Cummings G, Al-Sarraf M (1984). Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. *Cancer* 54 (5):811–814. [PubMed: 6204738]

41. Panis X, Coninx P, Nguyen TD, Legros M (1990). Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck. *Int J Radiat Oncol Biol Phys* 18 (6):1315–1318. [PubMed: 2370182]
42. Provencio M, Espana P, Millan I, Yebra M, Sanchez AC, de la Torre A, Bonilla F, Regueiro CA, de Letona JM (2004). Prognostic factors in Hodgkin's disease. *Leuk Lymphoma* 45 (6):1133–1139. [PubMed: 15359992]
43. Hasenclever D, Diehl V (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. *N Engl J Med* 339 (21):1506–1514. [PubMed: 9819449]
44. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A, Meloni G (1993). Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. *J Clin Oncol* 11 (11):2243–2249. [PubMed: 8229140]
45. Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. *Blood* 128 (12):1562–1566. [PubMed: 27432875]
46. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK (2012). Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. *Blood* 119 (26):6379–6381. [PubMed: 22611160]
47. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol* 17 (9):1283–1294. [PubMed: 27451390]

HIGHLIGHTS

- rrHL is responsive to salvage RT, with a low LF rate after moderate RT doses
- Overall survival of rrHL is excellent, despite refractory disease
- The response of rrHL to initial salvage therapy predicts subsequent LF
- Progression after omission of upfront RT or transplantation at failure can be salvaged

Fig. 1.

Example case. (A) Baseline PET/CT of a 15-year old with stage IIA Hodgkin lymphoma of the right cervical and mediastinal lymph nodes. (B) Complete metabolic response to both sites after reduced Stanford V chemotherapy. (C) Abnormal FDG uptake in the right cervical region 3 months after initial therapy. (D) Given partial anatomic response on CT after primary chemotherapy, she received involved- site radiation therapy (ISRT) to the mediastinum to 25.5 Gy. (E) After salvage chemotherapy and allogeneic hematopoietic cell transplant, she received ISRT to the right cervical region to 30.6 Gy. She has completed adjuvant brentuximab vedotin therapy and is currently without evidence of disease. PTV, planning target volume; 95% IDL, isodose line.

Fig. 2.

Cumulative incidence (CIN) and 5-year estimates of local failure (LF) after salvage irradiation for the overall cohort (A), for patients with adequate response to salvage chemotherapy (B), and patients with inadequate response to salvage chemotherapy (C). Patients with inadequate response experienced significantly higher LF rate (Gray's test, $p = 0.0475$). CI = confidence interval.

Fig. 3. Kaplan-Meier probability distributions of freedom from subsequent treatment failure (FFSTF) (A) and overall survival (OS) (B) after salvage irradiation, with 5-year estimates. CI = confidence interval.

Table 1.

Patient and treatment characteristics

Characteristic		N	% or Median (Range)
Age @ initial diagnosis		46	16.5 y (4.7–22.0 y)
Sex	Male	23	50.0%
	Female	23	50.0%
Race	White	33	72%
	Black	11	24%
	Other	2	4%
Histology	Nodular sclerosing	33	72%
	Classical, other	11	24%
	NLP	2	4%
Ann Arbor stage	I	4	8%
	II	21	46%
	III	10	22%
	IV	11	24%
B symptoms	No	23	50%
	Yes	23	50%
Extranodal disease	No	26	57%
	Yes	20	43%
Initial failure type	Progressive disease	10	22%
	Early relapse	18	39%
	Late relapse	18	39%
Initial failure site	Lymph node	32	70%
	Extranodal	2	4%
	Both	12	26%
New failure site	No	38	83%
	Yes	8	17%
Time to 1 st relapse		36	10.7 mo (1.2–42.7 mo)
Salvage transplant	No	9	20%
	Yes	37	80%
Frontline RT	No	6	13%
	Yes	32	70%
	Deferred	8	17%
RT dose/site	Frontline		25.5 Gy (8–30.6 Gy)
	Salvage		30.6 Gy (12–43.2 Gy)
Re-RT to any site	No	18	39%
	Yes	28	61%
Cumulative Re-RT Dose/site			56.1 Gy (41.1–68.7 Gy)

NLP, nodular lymphocyte predominant

Table 2.

Response to frontline and salvage regimens by patient (indicated in parentheses)

Frontline Therapy		Frontline Failure Type	First Salvage Therapy				Outcome
CT	RT		CT	RT	Transplant	Response to CT	
VAMP (6)	IFRT (28)	Progression (10)	MIED (17)	IFRT (22)	Yes(34)	CR/PR (38)	AWOD:
VAMP/COP (8)	ISRT (4)	Early Relapse (18)	Gem/Vin (18)	ISRT (15)	No (12)	SD/PD (8)	CR1 (3)
Stanford V (28)	None (14)	Late Relapse (18)	Stanford V (6)	TBI/ISRT (1)			CR2 (33)
OEPA/COPDac (2)			OEPA/COPDac (2)	None (8)			CR3 (4)
Other(2)			Benda/Brentux (2)				DOD (4)
			Other(1)				DWOD (2)

CT, chemotherapy; RT, radiation therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CR1–3, complete remission 1–3; AWOD, alive without disease; DOD, died of disease; DWOD, died without disease. Please see text for chemotherapy regimens and RT fields.

Table 3.

Cumulative incidence regression analysis of associations between clinical variables and local failure

Variable	HR	95% CI for HR	P-value
Age (continuous)	0.92	0.82–1.03	0.18
Sex (female vs. male)	7.84	1.01–60.90	0.049
Primary risk category	1.04	0.45–2.37	0.93
Response to 1 st salvage chemotherapy (inadequate vs. adequate)	0.25	0.065–0.98	0.048
Salvage RT dose: <30.6 vs. 30.6 Gy	3.87	0.72–20.70	0.11
Repeat RT (no vs. yes)	0.38	0.094–1.57	0.18
Autologous transplant (no vs. yes)	0.64	0.12–3.40	0.61
Primary progression vs. other	2.35	0.58–9.60	0.23
Early relapse vs. other	0.99	0.24–4.05	0.99
Late relapse vs. other	0.46	0.099–2.13	0.32

HR, hazard ratio; CI, confidence interval